Proud of the progress we’ve made together

At Nucleus Network, we’re proud of the contribution our teams and participants have made to medicine development over the years. Across our Australian and Minneapolis clinics, we have supported 351 studies for products that have since been approved for marketing in a major regulatory region such as the US, UK, EU, Japan or Canada — with these products now being used to treat patients.

Of these, 234 studies have been conducted in Australia and 117 in Minneapolis, highlighting the scale and global impact of the work taking place across our network.

This progress also extends to women’s health, where we have supported 24 approved products across areas including contraception, endometriosis, menopause and hormone therapy, female sexual dysfunction, breast and ovarian cancer, osteoporosis and more.

While every study represents an important step in the development process, seeing medicines we have supported go on to receive regulatory approval and reach patients is something we can all be proud of. It’s a reflection of the expertise, care and collaboration across Nucleus Network — and the contribution of the participants who make this work possible.